MedTrace Logo

Study to Compare the Efficacy & Safety of Ursoplus Capsules vs. UDCA vs. Placebo Among Chronic Liver Disease Patients

NCT05849558 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 297

Last updated 2023-05-09

No results posted yet for this study

Summary

This study aims to compare the efficacy \& safety of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA alone versus Placebo among Compensated Chronic Liver Diseased Patients

Conditions

Interventions

DRUG

Ursoplus

Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg)

DRUG

UDCA 250mg

UDCA 250mg alone

OTHER

Placebo

Placebo alone

Sponsors & Collaborators

  • MinaPharm Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Gamal Dr Esmat, PhD · Air Force Specialized Hospital

  • Mohamed El Kassas, PhD · Helwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-22
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05849558 on ClinicalTrials.gov